cALD trial update

A very important and promising update Minoryx Therapeutics presents positive interim results from NEXUS registration study for leriglitazone targeting pediatric ALD patients with cerebral adrenoleukodystrophy (cALD)

To read press release: https://www.minoryx.com/media/minoryx-presents-positive-interim-results-from-nexus/